{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:56:33Z","timestamp":1789390593843,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) heavily pretreated with anthracycline and taxanes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-arm, phase II study, patients with HER2-negative MBC previously treated with anthracycline and taxanes as second- to fifth chemotherapy received PLD (Duomeisu<jats:sup>\u00ae<\/jats:sup>, generic doxorubicin hydrochloride liposome) 40\u00a0mg\/m<jats:sup>2<\/jats:sup> every 4\u00a0weeks until disease progression, unacceptable toxicity, or completion of six cycles. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 44 enrolled patients (median age, 53.5\u00a0years; range, 34\u201369), 41 and 36 were evaluable for safety and efficacy, respectively. In total, 59.1% (26\/44) of patients had\u2009\u2265\u20093 metastatic sites, 86.4% (38\/44) had visceral disease, and 63.6% (28\/44) had liver metastases. Median PFS was 3.7\u00a0months (95% confidence interval [CI] 3.3\u20134.1) and median OS was 15.0\u00a0months (95% CI 12.1\u201317.9). ORR, DCR, and CBR were 16.7%, 63.9%, and 36.1%, respectively. The most common adverse events (AEs) were leukopenia (53.7%), fatigue (46.3%), and neutropenia (41.5%), with no grade 4\/5 AEs. The most common grade 3 AEs were neutropenia (7.3%) and fatigue (4.9%). Patients experienced palmar-plantar-erythrodysesthesia (24.4%, 2.4% grade 3), stomatitis (19.5%, 7.3% grade 2), and alopecia (7.3%). One patient displayed a left ventricular ejection fraction decline of 11.4% from baseline after five cycles of PLD therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PLD (Duomeisu<jats:sup>\u00ae<\/jats:sup>) 40\u00a0mg\/m<jats:sup>2<\/jats:sup> every 4\u00a0weeks was effective and well-tolerated in patients with HER2-negative MBC heavily pretreated with anthracycline and taxanes, revealing a potentially viable treatment option for this population.<\/jats:p>\n                <jats:p><jats:bold>Trial registration<\/jats:bold> Chinese Clinical Trial Registry: ChiCTR1900022568.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-06894-3","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T07:03:34Z","timestamp":1678086214000},"page":"67-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pegylated liposomal doxorubicin (Duomeisu\u00ae) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-7073","authenticated-orcid":false,"given":"Hanfang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-647X","authenticated-orcid":false,"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"6894_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA"},{"key":"6894_CR2","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1158\/0008-5472.Can-09-0099","volume":"69","author":"J Lu","year":"2009","unstructured":"Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J et al (2009) Breast cancer metastasis: challenges and opportunities. Cancer Res 69:4951\u20134953. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-0099","journal-title":"Cancer Res"},{"key":"6894_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","volume":"39","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J et al (2018) Global analysis of advanced\/metastatic breast cancer: decade report (2005\u20132015). Breast 39:131\u2013138. https:\/\/doi.org\/10.1016\/j.breast.2018.03.002","journal-title":"Breast"},{"key":"6894_CR4","doi-asserted-by":"publisher","first-page":"A619","DOI":"10.1016\/j.jval.2014.08.2189","volume":"17","author":"K Nersesyan","year":"2014","unstructured":"Nersesyan K, Robinson D, Pomerantz D (2014) Comparison of epidemiology and drug treatment in HER2 negative metastatic breast cancer (MBC) in EU5. Value Health 17:A619. https:\/\/doi.org\/10.1016\/j.jval.2014.08.2189","journal-title":"Value Health"},{"key":"6894_CR5","doi-asserted-by":"publisher","first-page":"062","DOI":"10.1093\/jncics\/pky062","volume":"2","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK et al (2018) Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr 2:062. https:\/\/doi.org\/10.1093\/jncics\/pky062","journal-title":"JNCI Cancer Spectr"},{"key":"6894_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"6894_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/d41573-019-00201-w","volume":"19","author":"CP Leo","year":"2020","unstructured":"Leo CP, Leo C, Szucs TD (2020) Breast cancer drug approvals by the US FDA from 1949 to 2018. Nat Rev Drug Discov 19:11. https:\/\/doi.org\/10.1038\/d41573-019-00201-w","journal-title":"Nat Rev Drug Discov"},{"key":"6894_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/s0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432\u2013444. https:\/\/doi.org\/10.1016\/s0140-6736(11)61625-5","journal-title":"Lancet"},{"key":"6894_CR9","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1001\/jamaoncol.2015.3062","volume":"1","author":"T Fujii","year":"2015","unstructured":"Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH et al (2015) Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis. JAMA Oncol 1:1311\u20131318. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3062","journal-title":"JAMA Oncol"},{"key":"6894_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000516419","volume":"16","author":"N Ditsch","year":"2021","unstructured":"Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M et al (2021) AGO Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2021. Breast Care (Basel) 16:214\u2013227. https:\/\/doi.org\/10.1159\/000516419","journal-title":"Breast Care (Basel)"},{"key":"6894_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"6894_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"6894_CR13","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/jco.2016.67.0182","volume":"34","author":"N Denduluri","year":"2016","unstructured":"Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA et al (2016) Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the cancer care Ontario clinical practice guideline. J Clin Oncol 34:2416\u20132427. https:\/\/doi.org\/10.1200\/jco.2016.67.0182","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"6894_CR14","doi-asserted-by":"publisher","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","volume":"24","author":"E Senkus","year":"2013","unstructured":"Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S et al (2013) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi7\u2013vi23. https:\/\/doi.org\/10.1093\/annonc\/mdt284","journal-title":"Ann Oncol"},{"key":"6894_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000502603","volume":"14","author":"D L\u00fcftner","year":"2019","unstructured":"L\u00fcftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R et al (2019) Treatment of early breast cancer patients: evidence, controversies, consensus: focusing on systemic therapy\u2014German experts\u2019 opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel) 14:315\u2013324. https:\/\/doi.org\/10.1159\/000502603","journal-title":"Breast Care (Basel)"},{"key":"6894_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/nejm199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900\u2013905. https:\/\/doi.org\/10.1056\/nejm199809243391307","journal-title":"N Engl J Med"},{"key":"6894_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/jnci\/djn206","volume":"100","author":"M Ryberg","year":"2008","unstructured":"Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058\u20131067. https:\/\/doi.org\/10.1093\/jnci\/djn206","journal-title":"J Natl Cancer Inst"},{"key":"6894_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/annonc\/mdn728","volume":"20","author":"PJ Barrett-Lee","year":"2009","unstructured":"Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N et al (2009) Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 20:816\u2013827. https:\/\/doi.org\/10.1093\/annonc\/mdn728","journal-title":"Ann Oncol"},{"key":"6894_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Update 29:90\u2013106. https:\/\/doi.org\/10.1016\/j.drup.2016.10.003","journal-title":"Drug Resist Update"},{"key":"6894_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1023\/a:1008216430806","volume":"9","author":"G Berry","year":"1998","unstructured":"Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B et al (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711\u2013716. https:\/\/doi.org\/10.1023\/a:1008216430806","journal-title":"Ann Oncol"},{"key":"6894_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419\u2013436. https:\/\/doi.org\/10.2165\/00003088-200342050-00002","journal-title":"Clin Pharmacokinet"},{"key":"6894_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440\u2013449. https:\/\/doi.org\/10.1093\/annonc\/mdh097","journal-title":"Ann Oncol"},{"key":"6894_CR23","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/jco.2005.03.8331","volume":"24","author":"S Chia","year":"2006","unstructured":"Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR et al (2006) Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24:2773\u20132778. https:\/\/doi.org\/10.1200\/jco.2005.03.8331","journal-title":"J Clin Oncol"},{"key":"6894_CR24","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/jco.2001.19.5.1444","volume":"19","author":"G Batist","year":"2001","unstructured":"Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444\u20131454. https:\/\/doi.org\/10.1200\/jco.2001.19.5.1444","journal-title":"J Clin Oncol"},{"key":"6894_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.10201","volume":"94","author":"L Harris","year":"2002","unstructured":"Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N et al (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25\u201336. https:\/\/doi.org\/10.1002\/cncr.10201","journal-title":"Cancer"},{"key":"6894_CR26","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/sj.bjc.6604409","volume":"98","author":"V Adamo","year":"2008","unstructured":"Adamo V, Lorusso V, Rossello R, Adamo B, Ferraro G, Lorusso D et al (2008) Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent\/metastatic breast cancer: a multicentre phase II study. Br J Cancer 98:1916\u20131921. https:\/\/doi.org\/10.1038\/sj.bjc.6604409","journal-title":"Br J Cancer"},{"key":"6894_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3816\/CBC.2009.n.042","volume":"9","author":"DA Yardley","year":"2009","unstructured":"Yardley DA, Burris HA 3rd, Spigel DR, Clark BL, Vazquez E, Shipley D et al (2009) A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. Clin Breast Cancer 9:247\u2013252. https:\/\/doi.org\/10.3816\/CBC.2009.n.042","journal-title":"Clin Breast Cancer"},{"key":"6894_CR28","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/annonc\/mdr024","volume":"22","author":"M Mart\u00edn","year":"2011","unstructured":"Mart\u00edn M, S\u00e1nchez-Rovira P, Mu\u00f1oz M, Baena-Ca\u00f1ada JM, Mel JR, Margeli M et al (2011) Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM\/2004-05 study. Ann Oncol 22:2591\u20132596. https:\/\/doi.org\/10.1093\/annonc\/mdr024","journal-title":"Ann Oncol"},{"key":"6894_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdt588","volume":"25","author":"CH Smorenburg","year":"2014","unstructured":"Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H et al (2014) A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol 25:599\u2013605. https:\/\/doi.org\/10.1093\/annonc\/mdt588","journal-title":"Ann Oncol"},{"key":"6894_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-016-4033-3","volume":"161","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Saupe S, J\u00e4ger E, Schmidt M, Kreienberg R, M\u00fcller L et al (2017) A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat 161:63\u201372. https:\/\/doi.org\/10.1007\/s10549-016-4033-3","journal-title":"Breast Cancer Res Treat"},{"key":"6894_CR31","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1200\/jco.2004.08.157","volume":"22","author":"AM Keller","year":"2004","unstructured":"Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A et al (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22:3893\u20133901. https:\/\/doi.org\/10.1200\/jco.2004.08.157","journal-title":"J Clin Oncol"},{"key":"6894_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3816\/cbc.2004.n.041","volume":"5","author":"M Martin","year":"2004","unstructured":"Martin M, Garc\u00eda-Donas J, Casado A, de la G\u00e1ndara I, P\u00e9rez-Segura P, Garc\u00eda-Saenz JA et al (2004) Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer 5:353\u2013357. https:\/\/doi.org\/10.3816\/cbc.2004.n.041","journal-title":"Clin Breast Cancer"},{"key":"6894_CR33","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","volume":"94","author":"SE Al-Batran","year":"2006","unstructured":"Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I et al (2006) The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 94:1615\u20131620. https:\/\/doi.org\/10.1038\/sj.bjc.6603158","journal-title":"Br J Cancer"},{"key":"6894_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00280-006-0236-3","volume":"58","author":"A Ardavanis","year":"2006","unstructured":"Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L et al (2006) Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Cancer Chemother Pharmacol 58:742\u2013748. https:\/\/doi.org\/10.1007\/s00280-006-0236-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"6894_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/01.coc.0000251400.47711.fe","volume":"30","author":"LW Chow","year":"2007","unstructured":"Chow LW, Yip AY, Lang BH (2007) A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer. Am J Clin Oncol 30:133\u2013138. https:\/\/doi.org\/10.1097\/01.coc.0000251400.47711.fe","journal-title":"Am J Clin Oncol"},{"key":"6894_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12885-015-1433-4","volume":"15","author":"KM Rau","year":"2015","unstructured":"Rau KM, Lin YC, Chen YY, Chen JS, Lee KD, Wang CH et al (2015) Pegylated liposomal doxorubicin (Lipo-Dox\u00ae) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study. BMC Cancer 15:423. https:\/\/doi.org\/10.1186\/s12885-015-1433-4","journal-title":"BMC Cancer"},{"key":"6894_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/tbj.12975","volume":"24","author":"P Martin-Romano","year":"2018","unstructured":"Martin-Romano P, Baraibar I, Espin\u00f3s J, Legaspi J, L\u00f3pez-Picazo JM, Aramend\u00eda JM et al (2018) Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience. Breast J 24:473\u2013479. https:\/\/doi.org\/10.1111\/tbj.12975","journal-title":"Breast J"},{"key":"6894_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH et al (2020) Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 18:452\u2013478. https:\/\/doi.org\/10.6004\/jnccn.2020.0016","journal-title":"J Natl Compr Cancer Netw"},{"key":"6894_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000093005","volume":"70","author":"SE Al-Batran","year":"2006","unstructured":"Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N et al (2006) Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70:141\u2013146. https:\/\/doi.org\/10.1159\/000093005","journal-title":"Oncology"},{"key":"6894_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"6894_CR41","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/s0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M (2017) Breast cancer. Lancet 389:1134\u20131150. https:\/\/doi.org\/10.1016\/s0140-6736(16)31891-8","journal-title":"Lancet"},{"key":"6894_CR42","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/sj.bjc.6605961","volume":"103","author":"SE Al-Batran","year":"2010","unstructured":"Al-Batran SE, G\u00fcntner M, Pauligk C, Scholz M, Chen R, Beiss B et al (2010) Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer 103:1518\u20131523. https:\/\/doi.org\/10.1038\/sj.bjc.6605961","journal-title":"Br J Cancer"},{"key":"6894_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/1471-2407-11-373","volume":"11","author":"M Fiegl","year":"2011","unstructured":"Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U, Steger GG (2011) Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. BMC Cancer 11:373. https:\/\/doi.org\/10.1186\/1471-2407-11-373","journal-title":"BMC Cancer"},{"key":"6894_CR44","doi-asserted-by":"publisher","first-page":"113388","DOI":"10.1016\/j.jpba.2020.113388","volume":"189","author":"Y Ji","year":"2020","unstructured":"Ji Y, Zhang X, Liu J, Chen Y, Meng M, Li C et al (2020) Direct quantitation of free, encapsulated, total doxorubicin and doxorubicinol in stabilized frozen human plasma to support a BE study of liposomal doxorubicin. J Pharm Biomed Anal 189:113388. https:\/\/doi.org\/10.1016\/j.jpba.2020.113388","journal-title":"J Pharm Biomed Anal"},{"key":"6894_CR45","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/annonc\/mds052","volume":"23","author":"RP Collea","year":"2012","unstructured":"Collea RP, Kruter FW, Cantrell JE, George TK, Kruger S, Favret AM et al (2012) Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. Ann Oncol 23:2599\u20132605. https:\/\/doi.org\/10.1093\/annonc\/mds052","journal-title":"Ann Oncol"},{"key":"6894_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K et al (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923. https:\/\/doi.org\/10.1016\/s0140-6736(11)60070-6","journal-title":"Lancet"},{"key":"6894_CR47","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/jco.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G et al (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33:594\u2013601. https:\/\/doi.org\/10.1200\/jco.2013.52.4892","journal-title":"J Clin Oncol"},{"key":"6894_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","volume":"112","author":"P Yuan","year":"2019","unstructured":"Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S et al (2019) Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur J Cancer 112:57\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2019.02.002","journal-title":"Eur J Cancer"},{"key":"6894_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"6894_CR50","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"6894_CR51","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/jco.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cortes J, Schmid P, Loirat D et al (2022) Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 40:3365\u20133376. https:\/\/doi.org\/10.1200\/jco.22.01002","journal-title":"J Clin Oncol"},{"key":"6894_CR52","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.Ccr-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N et al (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22:5097\u20135108. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2822","journal-title":"Clin Cancer Res"},{"key":"6894_CR53","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","volume":"6","author":"DM Goldenberg","year":"2015","unstructured":"Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM (2015) Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 6:22496\u201322512. https:\/\/doi.org\/10.18632\/oncotarget.4318","journal-title":"Oncotarget"},{"key":"6894_CR54","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K et al (2021) Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 32:1148\u20131156. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.002","journal-title":"Ann Oncol"},{"key":"6894_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.21147\/j.issn.1000-9604.2022.03.02","volume":"34","author":"Health Commission Of The People\u2019s Republic Of China N","year":"2022","unstructured":"Health Commission Of The People\u2019s Republic Of China N (2022) National guidelines for diagnosis and treatment of breast cancer 2022 in China (English version). Chin J Cancer Res 34:151\u2013175. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2022.03.02","journal-title":"Chin J Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06894-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T02:04:14Z","timestamp":1682733854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06894-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6894"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06894-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"assertion":[{"value":"10 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HPL received some part of the study drug for this trial from Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co. Ltd. All other authors declare that they have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Peking University Cancer Hospital (ID:2017YJZ08).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed an informed consent form regarding the publication of their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}